Multimillion Dollar Costs Predicted in Screening Mammography Litigation

News
Article
OncologyONCOLOGY Vol 16 No 12
Volume 16
Issue 12

In just 10 years, the cost of screening mammography litigation in the United States could top $250 million a year, a recent analysis has found. The analysis, presented at this year’s American Roentgen Ray Society meeting in Atlanta, is based on a

In just 10 years, the cost of screening mammography litigation in the United States could top $250 million a year, a recent analysis has found. The analysis, presented at this year’s American Roentgen Ray Society meeting in Atlanta, is based on a statistical model that reviewed the number of women likely to be undergoing mammograms, the potential for missed cancers, the average lawsuit settlement ($200,000 based on 1995 figures), and other similar factors.

"We are looking at a potential medical-legalmeltdown," said Richard Tello, md, msme, mph, professor of radiology,epidemiology, and biostatistics at Boston University. The baby boomers aregetting older, so the number of women needing mammograms is going up. As moremammograms are done, the potential for missed cancers increases, leading to anincreased chance of litigation.

Conservative Calculations

"We were conservative in our calculations—assumingthat only 1 in 10 women who are litigation candidates will sue, that half of thewomen who sue will have a lesion on a previous mammogram that was missed, andthat half of this subset will actually win their case," Dr. Tello said."These litigation costs could potentially go even higher," he added.

"The analysis found that $70 per woman per mammogram(assuming that about half of eligible women would have 20 mammograms over theirlifetimes) would need to be saved beginning now, to pay these futurecosts," Dr. Tello said. "The $70 figure is based on conservativeestimates; using less conservative estimates, we found that the amount neededcould be as high as $200 per woman per mammogram."

This is a major problem, because some insurance reimbursementfor mammograms is just at or near the $70 level, Dr. Tello explained. At thisrate, it is not economically feasible for radiologists to contribute to alitigation pool. It is unlikely that insurance companies will pay more toprepare for future litigation costs. Malpractice insurance companies wouldlikely increase their premiums as litigation costs go up, making it lessattractive for radiologists to even do screening mammgraphy, he noted.

One Solution

In addition, it is unlikely that the patient will payout-of-pocket to support a litigation pool, Dr. Tello said. A solution, however,could be a federally sponsored litigation pool similar to the one that currentlyexists for vaccine lawsuits.

"The study indicates that we need to act now to avoid acrisis in 10 years, when the costs of litigation force the shutdown ofmammography facilities nationwide," he said.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
Related Content